✦ LIBER ✦
Enoxaparin 0.3 mg/kg IV supplement for patients transitioning to PCI after subcutaneous enoxaparin therapy for NSTE ACS: A subgroup analysis from the SYNERGY trial
✍ Scribed by Marc Cohen; Glenn N. Levine; Karen S. Pieper; Lan Lan; Elliott M. Antman; Philip E. Aylward; Harvey D. White; Neal S. Kleiman; Robert M. Califf; Kenneth W. Mahaffey
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- English
- Weight
- 143 KB
- Volume
- 75
- Category
- Article
- ISSN
- 1522-1946
No coin nor oath required. For personal study only.